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Vertebrate eggs awaiting fertilization are arrested at metaphase of meiosis II by a biochemical activity termed cytostatic factor (CSF) 1, 2 . This activity inhibits the anaphase-promoting complex/ cyclosome (APC/C), a ubiquitin ligase that triggers anaphase onset and mitotic/meiotic exit by targeting securin and M-phase cyclins for destruction 3, 4, 5 . On fertilization a transient rise in free intracellular calcium 6 causes release from CSF arrest and thus APC/C activation. Although it has previously been shown that calcium induces the release of APC/C from CSF inhibition through calmodulin-dependent protein kinase II (CaMKII) 7, 8 , the relevant substrates of this kinase have not been identified. Recently, we characterized XErp1 (Emi2), an inhibitor of the APC/C and key component of CSF activity in Xenopus egg extract 9 . Here we show that calcium-activated CaMKII triggers exit from meiosis II by sensitizing the APC/C inhibitor XErp1 for polo-like kinase 1 (Plx1)-dependent degradation. Phosphorylation of XErp1 by CaMKII leads to the recruitment of Plx1 that in turn triggers the destruction of XErp1 by phosphorylating a site known to serve as a phosphorylation-dependent degradation signal. These results provide a molecular explanation for how the fertilization-induced calcium increase triggers exit from meiosis II.
Although it is well established that CaMKII is the essential target of the calcium signal 7, 8 on fertilization, the relevant substrates of this kinase have not been identified, and the mechanism(s) leading to APC/C activation have long remained obscure. Recently, we have identified XErp1, a novel component of CSF activity that is both necessary and sufficient to keep the APC/C inactive in CSF-arrested Xenopus egg extracts 9 (CSF extracts). In response to calcium, XErp1 is rapidly degraded via a Plx1-dependent mechanism, leading to CSF release and APC/C activation. We have further shown that XErp1 destruction depends on phosphorylation of two critical serine residues within a motif (DSGX 3 S) known to serve as a 'phosphodegron' for the ubiquitin ligase complex Skp1-Cullin-F-box
Although the identification of XErp1 as a critical substrate of Plx1 provided an attractive explanation for the essential function of Plx1 in APC/C activation 11 , the role of the calcium signal remained unclear. In particular, it remained to be explained why XErp1 is not targeted for degradation in CSF extracts, despite the presence of active Plx1 and SCF
b-TRCP
. Here we have explored the hypothesis that a calcium-dependent mechanism could sensitize XErp1 for phosphorylation by Plx1.
We first asked whether XErp1 could be a substrate of CaMKII. Autoradiographic analyses revealed that CaMKII efficiently phosphorylated purified maltose-binding protein (MBP)-tagged wildtype XErp1 but not MBP itself in vitro (Fig. 1a) . Together with our previous results that XErp1 degradation depends on its prior phosphorylation by Plx1 (ref. 9) , this result raised the question of how CaMKII and Plx1 cooperate in response to a calcium signal to target XErp1 for destruction. One attractive model was suggested by recent findings implicating the noncatalytic carboxy terminus of Plks, the so-called polo-box domain (PBD), in both Plk activation and the targeting of these kinases to serine-or threonine-phosphorylated substrates 12 . Based on this concept it was tempting to speculate that CaMKII sensitizes XErp1 for degradation by creating a binding site for Plx1. To explore this hypothesis, we examined the XErp1 sequence for sites that could potentially serve as CaMKII-regulated PBD binding sites (RXST/S; ref. 13) . Of the ten putative CaMKII phosphorylation sites (RXXS/T) (Fig. 1b) WT was rapidly degraded on anaphase onset whereas XErp1 mutated at its DSGX 3 S motif (XErp1 S33N,S38N ) was not targeted for calcium-induced degradation (Fig. 1c) . Notably, IVT XErp1
T195A , but not XErp1 T336A , remained stable on calcium addition (Fig. 1c) , indicating that Thr 195, but not Thr 336, is essential for the cell-cycle-regulated degradation of XErp1. As shown by microscopic analyses and by immunoblotting for cyclin B, all extracts had entered interphase on calcium addition (Fig. 1d, e) , confirming that the trace amounts of IVT products added did not block calcium-induced CSF release. Consistent with our previous observations 9 higher concentrations of XErp1 WT and XErp1
T195A
were capable of blocking calcium-induced CSF release (see Supplementary Fig. S1 ). Taken together, these data are consistent with the model that CaMKII and Plx1 cooperate to target XErp1 for degradation on a calcium stimulus and that Thr 195 and the DSGX 3 S motif are both required for the cell-cycle-regulated destruction of XErp1.
Previous studies have shown that phosphopeptide binding to the Plk-PBD is favoured by a serine residue in position 21 (SpT/pS; ref. 13 ). The above model thus predicted that Ser 194 might contribute to sensitizing XErp1 for Plx1-dependent degradation. Indeed, 35 Slabelled IVT XErp1 S194A remained stable in calcium-supplemented CSF extract (Fig. 2a, b ), similar to XErp1 T195A and XErp1 S33N,S38N . To prove that Plx1-binding to XErp1 depends on both Ser 194 and Thr 195, MBP-tagged wild-type protein and appropriate mutants were subjected to far-western experiments. Indeed, phosphorylation of XErp1
WT by CaMKII strongly enhanced the interaction between XErp1 and purified full-length Plx1. As expected, wild-type PBD (PBD WT ) but not a mutant form of PBD (PBD mut ) was capable of binding to phosphorylated XErp1
WT (Fig. 2c ). In contrast, both the S194A and T195A mutants of XErp1 treated with CaMKII failed to interact significantly with full-length Plx1 or PBD WT (Fig. 2c ), indicating that RXST 195 constitutes a CaMKII-regulated Plx1 binding site. Mutation of the DSGX 3 S motif did not interfere with the ability of XErp1 to bind to Plx1 or the PBD WT on phosphorylation by CaMKII (Fig. 2c ), in line with the expected order of events. Taken together, these data strongly suggest that CaMKII phosphorylation of XErp1 on Thr 195 creates a binding site for Plx1, consistent with the idea that CaMKII sensitizes XErp1 for Plx1-dependent degradation on anaphase onset.
An additional corollary of the proposed model is that PBD docking to XErp1 stimulates the kinase activity of Plx1 towards its substrate XErp1. To test this prediction, we used MBP-XErp1 with or without prior phosphorylation (with unlabelled ATP) by CaMKII to carry out Plx1 kinase assays in the presence of 32 P-labelled ATP. Compared to untreated XErp1 WT , XErp1
WT pre-phosphorylated by
CaMKII represented a much better in vitro substrate for Plx1 (Fig. 2d ) consistent with enhanced Plx1 recruitment after CaMKII phosphorylation. To rule out a contribution of CaMKII to the incorporation of 32 P into XErp1, parallel phosphorylation experiments were performed in the absence of Plx1. As shown in Fig. 2d , no labelling of XErp1 with 32 P was observed under these conditions. Notably, pretreatment of MBP-XErp1 S194A or -XErp1 T195A did not result in increased phosphorylation by Plx1 (Fig. 2d) , confirming the inability of these mutants to provide a docking site for Plx1. Taken together, these data demonstrate that calcium-activated CaMKII converts XErp1 into an efficient Plx1 substrate.
We next wanted to confirm that the activity of CaMKII is essential for the degradation of XErp1 on anaphase onset. However, as the inhibition of CaMKII prevents CSF release, and thus XErp1 degradation, we analysed the stability of IVT XErp1 in extract that was arrested at anaphase by the presence of non-degradable cyclin B (refs 14, 15) . These extracts, called 'D90 extracts' (refs 14, 15), retain WT or -XErp1 S194A was incubated in CSF extract in the presence or absence of calcium and samples were analysed by autoradiography (a) and microscopic examination of spindle and DNA morphology (b). c, Phosphorylation of XErp1 by CaMKII strongly enhances binding of Plx1 to XErp1. The binding of His-Plx1, MBP-PBD WT and MBP-PBD mut to MBPXErp1 was analysed by far-western ligand blots. MBP-XErp1 proteins were subjected to CaMKII phosphorylation reactions or mock treatments and resolved by SDS-PAGE. Bound Plx1 and PBD were detected using purified anti-Plx1 antibodies. d, MBP-XErp1 was subjected to in vitro phosphorylation reactions using recombinant Plx1. The incorporation of 32 P was analysed by autoradiography. As indicated, MBP-XErp1 was preincubated with activated CaMKII (or subjected to a mock kinase reaction) and unlabelled ATP. To control for incorporation of 32 P by CaMKII, parallel reactions were performed in the absence of Plx1.
CaMKII activity (see Supplementary Fig. S2 ) which can be modulated without affecting cell cycle progression. As expected, IVT XErp1
WT was rapidly degraded in D90 extracts (see Supplementary  Fig. S2 ). As most available specific CaMKII inhibitors are not able to inhibit activated CaMKII but only to prevent CaMKII activation we first suppressed CaMKII activity in D90 extracts by the addition of EGTA (see Supplementary Fig. S2 ), allowing us to study the effect of a specific CaMKII inhibitor on the stability of XErp1. Consistently, in the absence of an additional calcium stimulus IVT XErp1 WT remained stable in EGTA-treated D90 extracts, whereas it was rapidly degraded on calcium addition in a Thr 195-dependent manner (Fig. 3a) . Notably, the calcium-induced degradation of XErp1 WT could be significantly suppressed by the addition of 300 mM CaM-KII 281-309 (Fig. 3a) , a peptide known to specifically inhibit the calcium-induced activation of CaMKII (ref. 16 ). CaMKII activity assays demonstrated that CaMKII 281-309 prevented the calciuminduced reactivation of CaMKII (Fig. 3c) . The rapid degradation of IVT securin (Fig. 3a) under all conditions confirmed that the different treatments did not interfere with anaphase arrest. Furthermore, addition of a constitutively active form of CaMKII (CaMKII ) induced the rapid degradation of IVT XErp1
WT but not of XErp1 T195A (Fig. 3b) confirming that CaMKII is the kinase triggering XErp1 degradation on calcium stimulus. In view of an ongoing debate about a possible contribution of Emi1 to CSF activity 17 , we also used the above system to examine the fate of this XErp1-related protein. We found that CaMKII activity is not essential for the degradation of Emi1, as indicated by the fact that IVT Emi1 was efficiently degraded in EGTA-treated D90 extracts even without calcium addition (Fig. 3a) , or when the calcium-induced activation of CaMKII was suppressed by the addition of CaMKII ( Fig. 3a) . Taken together, these data suggest that XErp1, but not Emi1, is the critical target of calcium-activated CaMKII. This conclusion is in line with results showing that Emi1 is highly unstable in CSF-arrested extract 18, 19 , from which CaMKII activity is naturally absent. The observation that Emi1 stability does not seem to be regulated by CaMKII, together with results showing that Emi1 protein is unstable in CSF-arrested egg extract 18, 19 , argues against a critical contribution of Emi1 to CSF activity in Xenopus eggs.
The above data suggested that the lack of CaMKII activity accounts for the stability of XErp1 in CSF-arrested Xenopus egg extract. Consequently, we reasoned that a mutant XErp1 capable of serving as an efficient Plx1 substrate independently of CaMKII should be targeted for degradation in CSF extract even in the absence of a calcium signal. To test this idea, we converted the CaMKII site (RXST 195 LXD) into a consensus site for cyclin dependent kinase 1 (Cdk1; RXST 195 PXK) and examined the stability of the , -XErp1 T195A,L196P,D198K or -XErp1 S33N,S38N,L196P,D198K was incubated in CSF extract and samples were analysed by autoradiography. e-h Plx1 activity is required for the degradation of XErp1 L196P,D198K in CSF extract. e, f, Samples of CSF extracts supplemented with MBP-PBD WT or MBP-PBD mut were analysed (e) as in d, and assayed for DNA morphology (f). CSF extracts treated as in e were supplemented with calcium and assayed for the stability of IVT securin (g). Plx1-depleted (DPlx1) or mock depleted (control) CSF extract were treated as in d (h).
IVT product in CSF extracts. As Cdk1 is active in CSF extract and able to create docking sites for Plk-PBDs (ref. 13) , the prediction was that Cdk1-mediated phosphorylation of this mutant XErp1 would result in the docking of Plx1, the phosphorylation of the amino-terminal phospho-degron and the destruction of the protein. Indeed, whereas IVT XErp1
WT remained stable in CSF extract, XErp1 L196P,D198K was rapidly degraded even in the absence of calcium (Fig. 3d) , indicating that Cdk1 or any other proline-directed kinase active in CSF extract could substitute for CaMKII and sensitize this XErp1 mutant for Plx1-dependent degradation. As predicted by our model, the degradation of these XErp1 forms in CSF extract could be prevented by mutating either critical residues within the CDK1 consensus site (XErp1 T195A,L196P,D198K ) or the DSGX 3 S 38 motif (XErp1 S33N,S38N,L196P,D198K ) (Fig. 3d) . To demonstrate that the activity of Plx1 was essential for the degradation of XErp1 L196P,D198K , we examined the stability of IVT XErp1 L196P,D198K in CSF extract supplemented with an excess of MBP-PBD WT , which we have shown to exert a dominant-negative effect on Plx1 function 9 . As expected, the addition of MBP-PBD WT resulted in a significant stabilization of IVT XErp1 L196P,D198K in CSF extract, as compared to a controltreated extract (Fig. 3e ) but had no effect on the stability of IVT XErp1 WT (Fig. 3e) . Analyses of the chromatin structures revealed that the extracts remained CSF-arrested under all conditions (Fig. 3f) . The dominant-negative effect of MBP-PBD on Plx1 function was confirmed in parallel experiments in which we examined the stability of IVT securin on calcium addition. PBD WT -supplemented CSF extract, but not PBD mut -treated extract, failed to exit meiosis on calcium treatment, as indicated by stable IVT securin (Fig. 3g) . Consistently, MBP-PBD WT but not PBD mut prevented the calciuminduced degradation of endogenous XErp1 (see Supplementary  Fig. S3 ). Finally, a similar stabilization of IVT XErp1 L196P,D198K was observed in CSF extract immunodepleted of Plx1 but not in mockdepleted extract (Fig. 3h) . Taken together, these data demonstrate that the creation of a Plx1-PBD docking site on XErp1, an event normally brought about by calcium-activated CaMKII, defines the timing of Plx1-dependent degradation of XErp1.
In conclusion, our study identifies the critical substrate of the calcium-activated CaMKII that triggers exit from meiosis II in response to fertilization. Specifically, our data demonstrate that CaMKII phosphorylates the APC/C inhibitor XErp1, thereby acting as a novel priming kinase for the recruitment of Plx1 (Fig. 4) . The bound Plx1, previously shown to be essential for causing release from CSF arrest 11 , then triggers the degradation of XErp1 by phosphorylation of a DSGX 3 S degron. Our findings thus explain how a calcium signal prompts the exit from meiosis through the spatiotemporal integration of the action of two key kinases, CaMKII and Plx1, both converging onto XErp1, a critical inhibitor of APC/C.
METHODS
Plasmids, proteins and antibodies. XErp1, Emi1 and securin constructs were as described 9 . Site-directed mutagenesis was performed using the QuikChange kit (Stratagene). MBP-tagged proteins were purified following published protocols 9 . Purification of His-tagged Plx1 from SF9 cells was performed as described 11 . In-vitro translation experiments using 35 S-labelled methionine were performed according to manufacturer's protocol (Promega). Full-length Plx1 purified from SF-9 cells was used to generate rabbit antibodies to Plx1. MBP-PBD WT and MBP-PBD mut (W408F, H532A and K534A) were used as described previously 9 . In vitro kinase assays. CaMKII was purchased from New England biolabs. In vitro CaMKII assays were performed at 30 8C in kinase reaction buffer containing 45 U of activated CaMKII, 0.1-1 mM ATP, 4 mCi [g-32 P]ATP and 200 ng of purified MBP-tagged XErp1 protein. Samples were taken at the indicated time points. CaMKII activity assays were performed based on published protocols 8 using Autocamtide-2 (New England Biolabs) as substrate. Plx1 kinase assays were performed for 5 min at 30 8C using kinase reaction buffer supplemented with 4 mCi [g-32 P]ATP and MBP-tagged XErp1 proteins which had previously been incubated with CaMKII or buffer (control) in the presence of 1 mM ATP. Far-western ligand blots. Far-western ligand blots were performed in TBS supplemented with 0.1% Tween-20 and 5% wt/vol skim milk powder. For each assay 500 ng MBP-XErp1, treated with CaMKII or buffer (control), was subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to membranes. These were then incubated overnight at 4 8C with 2 mg ml 21 of MBP-tagged PBD 9 or His-Plx1. Bound protein was detected using affinity-purified rabbit antibodies to Plx1. Xenopus extracts. Xenopus CSF egg extracts were prepared as described previously 20 . CSF release was induced by adding 1 mM CaCl 2 to the extract. DNA and spindle morphology were examined as described previously 21 . CSFreleased extract was arrested at anaphase by the addition of non-degradable cyclin B (D90 extract) as described 14, 15 . The D90 extract was treated with 300 mM EGTA and CaMKII was re-activated by the addition of 600 mM calcium. Where indicated, MBP-PBD WT or MBP-PBD mut was added to the extract to a final concentration of 400 mg ml 21 . For some experiments extract was treated with cycloheximide. The immunodepletion of Plx1 was performed as described 22 . 
